Business Wire

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company has filed its Definitive Proxy Statement in connection with AIM’s ...
Seeking Alpha

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for ...

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The ...
Seeking Alpha

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

Thank you for your investment in AIM ImmunoTech Inc. (“AIM” or the “Company”). Your vote at this year’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for December 17, 2024, is ...
Business Wire

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”) today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange ...